ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy, and Pacing
- PMID: 39808105
- PMCID: PMC11998028
- DOI: 10.1016/j.jacc.2024.11.023
ACC/AHA/ASE/HFSA/HRS/SCAI/SCCT/SCMR 2025 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy, and Pacing
Abstract
This appropriate use criteria (AUC) document is developed by the American College of Cardiology along with key specialty and subspecialty societies. It provides a comprehensive review of common clinical scenarios where implantable cardioverter-defibrillator (ICD), cardiac resynchronization therapy (CRT), cardiac contractility modulation, leadless pacing, and conduction system pacing therapies are frequently considered. The 335 clinical scenarios covered in this document address ICD indications including those related to secondary prevention, primary prevention, comorbidities, generator replacement at elective replacement indicator, dual-chamber, and totally subcutaneous ICDs, as well as device indications related to CRT, conduction system pacing, leadless pacing, cardiac contractility modulation, and ICD therapy in the setting of left ventricular assist devices (LVADs).
The indications (clinical scenarios) were derived from common applications or anticipated uses, as well as from current clinical practice guidelines and results of studies examining device implantation. The indications in this document were developed by a multidisciplinary writing group and scored by a separate independent rating panel on a scale of 1 to 9 to designate care that is considered “Appropriate” (median 7 to 9), “May Be Appropriate” (median 4 to 6), and “Rarely Appropriate” (median 1 to 3). The final ratings reflect the median score of the 17 rating panel members.
In general, Appropriate designations were assigned to scenarios for which clinical trial evidence and/or clinical experience was available that supported device implantation. In contrast, scenarios for which clinical trial evidence was limited or device implantation seemed reasonable for extenuating or practical reasons were categorized as May Be Appropriate. Scenarios for which there were data showing harm, or no data were available, and medical judgment deemed device therapy was illadvised were categorized as Rarely Appropriate. For example, comorbidities including reduced life expectancy related to noncardiac conditions or severe cognitive dysfunction would negatively impact appropriateness ratings.
The appropriate use criteria for ICD, CRT, and pacing have the potential to enhance clinician decision making, healthcare delivery, and payment policy. Furthermore, recognition of clinical scenarios rated as May Be Appropriate facilitates the identification of areas where there may be gaps in evidence that would benefit from future research.
Keywords: ACC appropriate use criteria; cardiac resynchronization therapy; implantable cardioverter-defibrillator; pacing.
Similar articles
-
ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance.Heart Rhythm. 2013 Apr;10(4):e11-58. doi: 10.1016/j.hrthm.2013.01.008. Epub 2013 Mar 7. Heart Rhythm. 2013. PMID: 23473952 Review. No abstract available.
-
ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance.J Am Coll Cardiol. 2013 Mar 26;61(12):1318-68. doi: 10.1016/j.jacc.2012.12.017. Epub 2013 Mar 1. J Am Coll Cardiol. 2013. PMID: 23453819 No abstract available.
-
ACC/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2024 Appropriate Use Criteria for Multimodality Imaging in Cardiovascular Evaluation of Patients Undergoing Nonemergent, Noncardiac Surgery.J Am Coll Cardiol. 2024 Oct 8;84(15):1455-1491. doi: 10.1016/j.jacc.2024.07.022. Epub 2024 Aug 26. J Am Coll Cardiol. 2024. PMID: 39207318 No abstract available.
-
ACC/AHA/ASE/ASNC/ASPC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2023 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Chronic Coronary Disease.J Am Coll Cardiol. 2023 Jun 27;81(25):2445-2467. doi: 10.1016/j.jacc.2023.03.410. Epub 2023 May 25. J Am Coll Cardiol. 2023. PMID: 37245131 No abstract available.
-
Society for Cardiovascular Magnetic Resonance perspective on the ACC/AHA/ASE/ASNC/ASPC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2023 multi-modality appropriate use criteria for the detection and risk assessment of chronic coronary disease.J Cardiovasc Magn Reson. 2023 Oct 19;25(1):59. doi: 10.1186/s12968-023-00959-4. J Cardiovasc Magn Reson. 2023. PMID: 37858255 Free PMC article. Review. No abstract available.
Cited by
-
Cardiac implantable electronic devices in the setting of tricuspid valve intervention: Risks, options, extraction and future perspectives: A state-of-the-art review.Heart Rhythm O2. 2025 Feb 28;6(6):880-892. doi: 10.1016/j.hroo.2025.02.016. eCollection 2025 Jun. Heart Rhythm O2. 2025. PMID: 40717859 Free PMC article. Review.
-
Reply: The Impact of EAT, NYHA Functional Class, and Inflammation on VT/VF in NICMP Patients.JACC Adv. 2025 Aug;4(8):101992. doi: 10.1016/j.jacadv.2025.101992. Epub 2025 Jul 11. JACC Adv. 2025. PMID: 40651320 Free PMC article. No abstract available.
References
-
- Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2013;61:1318–1368. - PubMed
-
- Hendel RC, Lindsay BD, Allen JM, et al. ACC appropriate use criteria methodology: 2018 update: a report of the American College of Cardiology Appropriate Use Criteria Task Force. J Am Coll Cardiol. 2018;71:935–948. - PubMed
-
- Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients With ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72:e91–e220. - PubMed
-
- Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51:e1–e62. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials